Provide initial clinical data from the Phase I/IIa trial of AMT-191
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 23 Sep 2024
- Due
- 31 Dec 2025
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“providing initial data in 2025”
What we found
Evidence strength A What the grades mean
The company announced initial safety and exploratory efficacy data from the first cohort of the AMT-191 Phase I/II clinical trial in September 2025, meeting the 2025 deadline.
-
A uniQure N.V. 8-K filed 2026-01-13
“Presented initial data from AMT-191 Fabry study in 3Q25” ✓ confirmed on the page
-
A uniQure N.V. 10-K filed 2026-03-02
“In September 2025, we announced initial safety and exploratory efficacy data from the first cohort.” ✓ confirmed on the page
Market reaction: the shares moved -4.2% against the S&P 500 over the three sessions around the disclosure (12 Jan 2026 to 15 Jan 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 23 Sep 2024
Deadline 31 Dec 2025 (“in 2025”)
-
Version 2 · stated 10 Nov 2025
Deadline 30 Jun 2026 (“in the first half of 2026”) · wording expected
“The Company expects to present updated results from the Phase I/IIa clinical trial in the first half of 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- initial clinical data for AMT-191
- Where
- United States
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001887 · Corrections policy